Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: Experiences from the RE-LY trial
Ziad Hijazi(Uppsala University), Lars Wallentin(Uppsala University), Paolo Verdecchia(Azienda Ospedaliera di Perugia), Gianpaolo Reboldi(Ca' Foncello Hospital), Stuart J. Connolly(Population Health Research Institute), Jonas Oldgren(Uppsala University), John W. Eikelboom(Population Health Research Institute), Fabio Angeli(University of Insubria), Ulrika Andersson(Uppsala University), Giuseppe Di Pasquale, Salim Yusuf(Population Health Research Institute), Giovanni Mazzotta(University of Perugia), Michael D. Ezekowitz(Lankenau Institute for Medical Research)
Cited by 22
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k